EXTON, Pa., January 30, 2012 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announces that the June 2011 FDA approval of LAVIV™ (azficel-T) for the improvement of the appearance of “smile line” wrinkles was named the #3 top story of 2011 in cell and gene therapy and regenerative medicine at The 2012 Cell & Gene Therapy Forum in Washington, D.C. The award was voted by The Cell & Gene Therapy Forum survey responders, comprised of Director-level and above leaders in the cell and gene therapy and regenerative medicine industry. The meeting is organized annually by Phacilitate (www.phacilitate.co.uk), a specialist in the organization of exclusive events (www.phacilitate.co.uk/cgt) for leaders from the life sciences community.

 “We are delighted and honored that industry leaders attending The 2012 Cell & Gene Therapy Forum have recognized the FDA approval of LAVIV and we hope we continue to impress the industry with our innovations in upcoming years,” said David Pernock, Fibrocell Science Chairman and CEO. “Fibrocell Science is committed to exploring the full therapeutic potential of our personalized fibroblast cellular treatment for use in diverse medical and aesthetic applications.”

About LAVIV

 Approved on June 21, 2011, LAVIV™ (azficel-T) is the first and only personalized cell therapy approved by the FDA for aesthetic use. It is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles (“smile lines”), in adults. The patented technology behind LAVIV is an advanced process that extracts a person’s collagen-producing fibroblast cells from a small skin sample and multiplies them in the Fibrocell Science lab. (The collagen produced by fibroblast cells helps give skin its tone, structure and overall quality. As people get older, the number of fibroblasts decreases and collagen breaks down, resulting in wrinkles and lost skin tone. ) LAVIV is the resulting formulation of a person’s own fibroblast cells, which is then injected into “smile line” wrinkles.

 LAVIV is now available in major metropolitan areas throughout the U.S., exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science on the treatment process. A list of trained and certified physicians is available at www.mylaviv.com and will be continually updated as new physicians are trained and begin offering LAVIV in their practice.

Important Safety Information About LAVIV™ (azficel-T)

LAVIV is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Prior to injection, confirm with your physician that your information on the LAVIV vial is correct.

 The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment.

 Your health care provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV. Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or coumadin, keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these warnings.

 Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse. For more information about LAVIV, please see the Full Prescribing Information at www.mylaviv.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

Fibrocell’s presentation is scheduled for Wednesday, January 11, 2012 at 10:00 AM Pacific Time.

 The presentation will be webcast live, and a replay will be available during the week of January 9 at www.onemedplace.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications.  Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence.  For additional information, please visit www.fibrocellscience.com.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
(646) 277-1247
sherry.bertner@icrinc.com

Fibrocell’s presentation is scheduled for Wednesday, December 14, 2011 at 11:25 AM Eastern Time.

The presentation will be webcast live, and a replay will be available on the Investors section of the Company’s website at www.fibrocellscience.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
(646) 277-1247
sherry.bertner@icrinc.com

Fibrocell’s presentation is scheduled for 3:40 p.m. Pacific Time.

The presentation will be webcast live, and a replay will be available on the Investors section of the Company’s website at www.fibrocellscience.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB: FCSC) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
(646) 277-1247
sherry.bertner@icrinc.com

Fibrocell invites all interested parties to join the call by dialing 877-705-6003 for domestic participants and 201-493-6725 for international participants. The call will also be broadcast live over the Internet and can be accessed on the Investors section of the Company’s website at www.fibrocellscience.com.

A telephone replay will be available for two weeks following the call by dialing 877-870-5176 for domestic participants and 858-384-5517 for international participants. When prompted, please enter replay pin number 382655. For those who are not available to listen to the live webcast, the call will be archived for 90 days on Fibrocell’s website.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (FCSC.OB) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
(646) 277-1247
sherry.bertner@icrinc.com

EXTON, Pa., November 03, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced that clinical trial data demonstrating the effectiveness of LAVIV™ (azficel-T) for the improvement of the appearance of moderate-to-severe nasolabial fold wrinkles (“smile lines”) was presented late Friday afternoon at the 2011 American Society of Dermatologic Surgery Annual Meeting in Washington, D.C. LAVIV is a breakthrough new treatment for “smile line” wrinkles made from a person’s own collagen producing skin cells and is the first and only personalized cell therapy approved by the FDA for aesthetic use.

Study investigator Stacy Smith, M.D., presented results from secondary analyses of data from treated patients who participated in two pivotal LAVIV clinical studies, showing that 64% and 78% of patients treated with LAVIV experienced one-point improvements on the 6-point investigator scale and 5-point patient assessment scale, respectively, when assessed six months after completing LAVIV study treatment. Placebo rates were 36% and 48%, respectively.

Dr. Smith also presented the results of the co-primary efficacy assessments from these studies; the same data that are used in the FDA-approved Prescribing Information for LAVIV. The co-primary efficacy analyses required a robust two-point improvement in both assessments. Based on this standard, 30% of subjects who received at least one LAVIV injection had a two-point improvement in the appearance of smile lines six months after completing treatment, as rated by investigators, versus 8% for placebo. In self-assessments, 59% of patients reported a two-point improvement on a 5-point scale six months after completing treatment, versus 26% for placebo.

“LAVIV is a first of its kind treatment that works by expanding a patient’s own collagen-producing fibroblast cells. This data confirms the effectiveness of this innovative cell therapy,” said Dr. Smith, Associate Clinical Professor in the Division of Dermatology at the University of California, San Diego. “Since LAVIV is made from a patient’s own collagen-producing fibroblast cells, the safety profile is excellent,” he added.

In the safety data from the studies presented at ASDS, the most common adverse events were mild to moderate injection site reactions. Adverse events reported by more than 1% of patients treated with LAVIV included injection site redness (20%), swelling (12%), bleeding (6%), bruising (4%), papules (3%), pain (3%), and irritation (2%). Ninety-four percent (94%) of all adverse events reported by patients treated with LAVIV resolved within one week. In a microscopic analysis of the skin in the injected area, cells characteristic of mild inflammation were seen in 50% of samples treated with LAVIV, but no evidence of significant adverse changes was observed.

The patented technology behind LAVIV is an advanced process that extracts a person’s fibroblast cells from a small skin sample and multiplies them in the Fibrocell Science lab. In normal skin, fibroblasts are responsible for producing collagen. LAVIV is the resulting formulation of a person’s own fibroblast cells, which is then injected into smile line wrinkles. Each person’s formulation of LAVIV is unique because it is made from their own fibroblast cells.

“We are delighted to share the results of the rigorously-designed LAVIV clinical trials to showcase the efficacy and safety of this innovative and highly personalized way to treat smile lines,” said David Pernock, Fibrocell Science Chairman and CEO.

About the Studies

The two, identical, Phase III multi-center, randomized, double-blind, placebo-controlled studies randomized 421 patients to receive LAVIV or placebo. The data presented at ASDS are from the modified-intent-to-treat analysis, which included 372 treated patients. Treatment was administered in three sessions approximately five weeks apart. Product efficacy was assessed by both patients and evaluating physicians. A subset of patients from these studies provided tissue samples for a histology analysis, which provided information about the skin after treatment on a cellular level. Safety data reported from this study were consistent with the adverse event profile established for LAVIV in previous clinical studies.

Data from these studies that supported approval and appear in the LAVIV Prescribing Information are from the more conservative intent-to-treat population, which included all 421 patients, regardless of whether or not they received treatment.

About LAVIV™ (azficel-T)

LAVIV was approved by the FDA on June 21, 2011, for the improvement of the appearance of moderate-to- severe nasolabial fold (smile line) wrinkles in adults. LAVIV is now available in major metropolitan areas throughout the U.S., exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science on the treatment process. A list of trained and certified physicians will soon be available at www.mylaviv.com and will be continually updated as new physicians are trained and begin offering LAVIV in their practice.

Important Safety Information About LAVIV™ (azficel-T)

LAVIV (azficel-T) is an autologous cellular product indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

LAVIV is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Prior to injection, confirm with your physician that your information on the LAVIV vial is correct.

The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment.

Your health care provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV. Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or coumadin, keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these warnings.

Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse.

For more information about LAVIV, please see the Full Prescribing Information at www.mylaviv.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (FCSC.OB) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

Forward Looking Statements

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the future appeal of LAVIV, the Company’s ability to increase manufacturing, to increase the number of physicians trained and to expand the number of cities served. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
(646) 277-1247
sherry.bertner@icrinc.com

EXTON, Pa., November 03, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, today announced the first scientific presentation of data demonstrating the efficacy of LAVIV™ (azficel-T) in treating moderate-to-severe depressed acne scars. The data were presented at the American Society for Dermatologic Surgery (ASDS) annual meeting in Washington, D.C. LAVIV, which is made from a person’s own collagen-producing skin cells, is the first and only personalized cell therapy approved by the FDA for aesthetic use and was recently approved for the improvement of the appearance of moderate-to-severe “smile line” wrinkles (nasolabial folds). LAVIV is being investigated for the treatment of rolling, depressed acne scars, but is not currently approved for this indication.

According to the American Academy of Dermatology, about 40 to 50 million Americans have acne at any one time. Rolling acne scars are caused by damage under the surface of the skin and appear as soft, saucer-like depressions or pits on the skin. The skin typically loses its underlying support and develops a wavy texture. The scars tend to be wide and shallow. Research shows that facial acne scarring is common and affects men and women equally, occurring to some degree in 95 percent of acne cases. In this study, LAVIV was injected into the facial acne scars of patients to smooth the skin depressions.

The study successfully met its two prospectively defined co-primary endpoints: a 2-point or greater improvement on a 5-point Subject Live Acne Scarring assessment scale and a 1-point or greater reduction in cheek acne severity on a physician-assessed, validated 5-point Evaluator Live Acne Scar assessment scale. Final assessments were conducted four months after completing the study treatment regimen.

“Common approaches to treat acne scarring such as laser and fractional resurfacing can lead to prolonged downtime or unpredictable pigmentary complications of the skin,” said Girish (Gilly) Munavalli, M.D., Medical Director, Dermatology, Laser, and Vein Specialists of the Carolinas, PLLC, Assistant Professor of Dermatology at Wake Forest University School of Medicine, and investigator for the study. “Our findings show that using a person’s own collagen-producing cells in the form of LAVIV may provide a promising new alternative to improve acne scarring with minimal downtime and an excellent safety profile.”

According to the study results, a statistically significant higher percentage of subjects responded to treatment with LAVIV than with placebo, as rated by both the study investigators (58.7% vs. 42.2%; p=0.016) and patients (43.1% vs. 18.3%; p=0.000011) at the final assessment. Patient and Evaluator assessments at earlier time points during the study also showed a statistically significant higher proportion of responses with LAVIV than with placebo at all but one assessment.

All adverse events (AEs) reported during the study were mild or moderate in severity. No subjects experienced serious adverse events, discontinued treatment, or withdrew from the study as a result of an AE. The incidence of adverse events occurring in the treatment areas was comparable between LAVIV and placebo. The most common reported AEs were treatment area erythema (occurring in 11.1% of subjects) and swelling (occurring in 10.1% of subjects). Five of the 12 subjects reporting erythema and five of the 11 subjects reporting swelling had events of moderate severity in the LAVIV-treated area, whereas all treatment related AEs reported in the placebo-treated area were of mild severity. Other AEs reported during the study with a possible relationship to study treatment included bruising, rash, irritation, nodule, pain, acne, induration and headache. No clinically meaningful changes in vital signs or physical exam findings were reported.

The patented technology behind LAVIV is an advanced process that extracts a person’s fibroblast cells from a small skin sample and multiplies them in the Fibrocell Science lab. In normal skin, fibroblasts are responsible for producing collagen. LAVIV is the resulting formulation of a person’s own fibroblast cells. Each person’s formulation of LAVIV is unique because it is made from their own cells.

“Fibrocell Science is committed to exploring the full therapeutic potential of our personalized fibroblast cellular treatment for use in diverse medical and aesthetic applications,” said David Pernock, Fibrocell Science Chairman and CEO. “We are encouraged by these data and look forward to further investigating the potential role of LAVIV in treating of acne scars.”

About the Study

The major clinical trial was a multi-center, randomized, double-blind, placebo-controlled study, enrolling and collecting skin biopsies from 119 patients who had moderate-to-severe depressed acne scarring on both sides of the face for at least three years. Skin biopsies obtained from enrolled patients were used for fibroblast production. Patients served as their own controls. Ninety-nine of these patients received up to three injections with 2 mL autologous fibroblasts (10 – 20 million cells/mL) on one cheek and placebo (vehicle control; dye-free cell culture media) on the other at 14 day intervals. Treatment was administered at a dose of 0.1mL/cm2 into areas of acne scarring on the cheek, which were required have a scarred area of at least 9 cm2. Efficacy was assessed as described above. Safety was assessed based on the incidence of adverse events collected throughout the trial. Any injection site reactions or other localized adverse events were recorded independently for each side of the face, so that a comparison of adverse events by treatment could be performed.

Important Safety Information About LAVIV™ (azficel-T)

LAVIV (azficel-T) is an autologous cellular product indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

LAVIV is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Prior to injection, confirm with your physician that your information on the LAVIV vial is correct.

The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment.

Your health care provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV. Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or coumadin, keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these warnings.

Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse.

For more information about LAVIV, please see the Full Prescribing Information at www.mylaviv.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (FCSC.OB) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

Forward Looking Statements

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the future appeal of LAVIV, the Company’s ability to increase manufacturing, to increase the number of physicians trained and to expand the number of cities served. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
(646) 277-1247
sherry.bertner@icrinc.com

Conference call to discuss LAVIV business strategy to be held October 4, 2011 at 5:00 PM

EXTON, Pa., October 03, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that it has begun the launch of LAVIV™ (azficel-T) in major metropolitan areas throughout the U.S. LAVIV is a revolutionary treatment for “smile line” wrinkles made from a person’s own skin cells and was approved by the FDA on June 21, 2011 as the first and only personalized cell therapy for use in aesthetics. LAVIV was recently named a 2011 Allure Best of Beauty Award winner in the magazine’s annual cover story (October 2011 issue).

“We will be offering LAVIV exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science on the treatment process. We are launching initially in key cities across the country and are on track to expand into other markets in 2012 as more physicians are trained and manufacturing capacity increases,” said David Pernock, Fibrocell Science Chairman and CEO. “Our goal is to provide excellent customer service to the physicians we work with, and a high level of satisfaction to the patients they treat.”

The patented technology behind LAVIV is an advanced process that extracts a person’s fibroblast cells from a small skin sample and multiplies them in the Fibrocell Science lab. In normal skin, fibroblasts are responsible for producing collagen. LAVIV is the resulting formulation of a person’s own fibroblast cells, which is then injected into smile line wrinkles. Each person’s formulation of LAVIV is unique because it is made from their own cells.

“LAVIV offers an entirely new approach to smoothing smile line wrinkles and we are thrilled to be making this personalized treatment more widely available,” added Mr. Pernock. “To date, we have received very positive feedback from physicians who are offering LAVIV in their practices now, or who want to begin offering it.”

With LAVIV now available, Fibrocell Science, Inc. has also launched mylaviv.com, a new resource for interested patient candidates. This website includes product information, frequently asked questions and will soon feature a physician finder, which will be continually updated as new physicians are trained and begin offering LAVIV in their practices.

Conference Call

Mr. Pernock will host an investor conference call to discuss LAVIV business strategy tomorrow, Tuesday, October 4th, at 5:00 PM Eastern Time. Fibrocell Science, Inc. invites all interested parties to join the call by dialing 888-329-8903 for domestic participants and 719-457-2731 for international participants. They will also broadcast the call live over the Internet. The investor conference call can be accessed on the Investors section of Fibrocell Science’s website at www.fibrocellscience.com.

A telephone replay will be available for two weeks following the call by dialing 877-870-5176 for domestic participants and 858-384-5517 for international participants. When prompted, the Company requests that those interested enter replay pin number 2826334. For those who are not available to listen to the live webcast, the call will be archived for 90 days on Fibrocell Science, Inc.’s corporate website.

Important Safety Information About LAVIV™ (azficel-T)

LAVIV is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Do not let anyone else use your LAVIV.

The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment.

Your health care provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV. Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or coumadin, keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these warnings.

Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse.

For more information about LAVIV, please see the Full Prescribing Information at www.mylaviv.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (FCSC.OB) is a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

Forward Looking Statements

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the future appeal of LAVIV, the Company’s ability to increase manufacturing, to increase the number of physicians trained and to expand the number of cities served. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.

CONTACTS:

Media
Marina Maher Communications
Christina Fuschetto
(212) 485-6917
cfuschetto@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
Managing Director
(646) 277-1247
sherry.bertner@icrinc.com

EXTON, Pa., September 28, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that LAVIV™ (azficel-T) has been named a 2011 Allure Breakthrough Award winner. LAVIV™ is a revolutionary new treatment for “smile line” wrinkles made from a person’s own skin cells that was recently FDA-approved.

The patented technology behind LAVIV™ is an advanced process that extracts a person’s fibroblast cells from a small skin sample and multiplies them in the Fibrocell Science lab. In normal skin, fibroblasts are responsible for producing collagen. LAVIV™ is the resulting formulation of a person’s own fibroblast cells, which is then injected into smile line wrinkles – the lines that run from the sides of the nose to the corners of the mouth. Each person’s formulation of LAVIV™ is unique because it is made from their own cells.

“We are thrilled that Allure recognized LAVIV™ with the Breakthrough Award. LAVIV™ offers a very new, highly personalized approach to treating smile line wrinkles, which is clinically proven to be safe and effective,” said David Pernock, Fibrocell Science Chairman and CEO.

Allure, the first and only magazine devoted to beauty, publishes its Best of Beauty Awards annually in the October issue. LAVIV™ is one of 14 Big Breakthrough products and treatments honored by Allure’s editorial staff.

About LAVIV™ (azficel-T)

LAVIV™ was approved by the FDA on June 21, 2011 for the improvement of the appearance of moderate to severe smile line (nasolabial fold) wrinkles in adults.

Important Safety Information

LAVIV™ is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Do not let anyone else use your LAVIV™.

The most common side effects of LAVIV™ are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV™, most injection-site adverse reactions resolved within one week and most required no treatment.

Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide (DMSO). Do not use LAVIV™ if you have a skin infection on your face because LAVIV™ treatment can make the infection worse.

For more information about LAVIV™, please see the Full Prescribing Information at www.myLAVIV.com.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (FCSC.OB) is a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

Forward Looking Statements

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the future appeal of LAVIV™, the Company’s ability to increase manufacturing, to increase the number of physicians trained and to expand the number of cities served. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.

CONTACTS:
Media
Marina Maher Communications
Christina Fuschetto
(212) 485-6917
cfuschetto@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
Managing Director
(646) 277-1247
sherry.bertner@icrinc.com

David Pernock, the Company’s Chairman and CEO, is now scheduled to present on Tuesday, September 20, at 12:00 p.m. Eastern Time.

The presentation will be webcast live, and a replay will be available on the Investors section of the Company’s website at www.fibrocellscience.com

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTCBB:FCSC.OB) is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

CONTACTS:

Media
Marina Maher Communications
Jessica Morrison
(212) 485-6806
jmorrison@mahercomm.com

Investors
ICR, LLC
Sherry Bertner
Managing Director
(646) 277-1247
sherry.bertner@icrinc.com